Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis

@article{Menshawy2017EfficacyAS,
  title={Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis},
  author={Amr Menshawy and Ammar . Ismail and Abdelrahman Ibrahim Abushouk and Ahmed Hussien Hanafy Ahmed and Esraa Menshawy and Ahmed Elmaraezy and Mohamed Gadelkarim and Mohamed Abdel-Maboud and Attia S. Attia and Ahmed Negida},
  journal={Archives of Virology},
  year={2017},
  volume={162},
  pages={2181-2190}
}
Atazanavir (ATZ) is a well-tolerated protease inhibitor that can be boosted with ritonavir (r) to treat infection with resistant strains of human immunodeficiency virus 1 (HIV-1). The aim of this meta-analysis was to compare the efficacy, safety, and metabolic effects of ATZ/r regimen versus commonly used antiretroviral drugs such as lopinavir (LPV) and darunavir (DRV) in HIV-1-infected patients. We searched PubMed, Scopus, Embase and Cochrane CENTRAL, using relevant keywords. Data were… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

96-week efficacy and safety results of the CASTLE study

  • Molina J-M, J Andrade-Villanueva, Echevarria J et al Once-daily atazanavirritonavir compared wi lopinavirritonavir, each in combination with tenofovir, emtricitabine, for management of antiretroviral-naive HIV-1-infected patients
  • J Acquir Immune Defic Syndr
  • 1999
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…